KCT0008883尚未招募Unknown
Post-transplant therapy with hypomethylating agent in Philadelphia chromosome negative adult acute lymphoblastic leukemia
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 33
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 70(Year)（—）
- 性别
- All
入选标准
- •1) Patients who consented to the study
- •2) Age > 19, <70
- •3) Patients who diagnosed Philadelphila chromosome negative acute lymphoblastic leukemia and received standard chemotherapy
- •4) Complete remission status after allogeneic stem cell transplantation
- •5) Bone marrow blast < 5% after allogeneic stem cell transplantation & Patients who can receive decitabine (ANC > 1,000/uL & PLT > 50,000/uL)
- •6) Patients less than 100 days after allogeneic stem cell transplantation
- •7) Eastern Cooperative Oncology Group (ECOG) performance status 0-2
- •8) Patients with appropriate liver, kidney, heart function
- •9) A person who understands the contents of the clinical trial, is cooperative with the trial progress, and is judged to be able to participate until the end of the study
排除标准
- •1) Pregnant or lactating women, or women who may become pregnant without adequate contraception
- •2) Previous history of hypomethylation treatment
- •3) Patients who have developed other malignant tumors within the past 5 years, excluding basal cell carcinoma of the skin, cervical carcinoma in situ, and papillary thyroid cancer that have been completely treated with the intention of cure
- •4) Other serious illnesses or medical conditions
- •5) Patients 100 days after allogeneic hematopoietic stem cell transplantation
- •6) Men who want to become pregnant or donate sperm during a clinical trial
- •7) Co-administration of other experimental drugs in clinical trials
- •8) Any other person deemed unsuitable by the researcher.
研究者
相似试验
进行中（未招募）
不适用
Treatment of patients with post-transplant lymphoproliferative disorder (PILD) with a sequential treatment consisting of anti-CD20 antibody rituximab and CHOP + GCSF chemotherapy (including first, second and third amendment).EUCTR2005-000743-29-BEHeads Study Group
已完成
不适用
Pre-treatment of deceased organ donors with methylprednisolone versus placebo for the prevention of post-ischemic acute renal transplant failurePre-treatment of deceased organ donorsNutritional, Metabolic, EndocrinePrevention of post-ischaemic acute renal transplant failureISRCTN78828338Austrian Science Fund200
已完成
不适用
Safety and efficacy of mycophenolate mofetil in pediatric renal transplantation.NL-OMON29296/A44
尚未招募
不适用
Role of hypomethylating agents to improve survival outcomes in patients with high-risk acute myeloid leukemia who underwent allogeneic stem cell transplantatioDiseases of the blood and blood -forming organs and certain disorders involving the immune mechanismKCT0004821Kyungpook National University Hospital90
进行中（未招募）
1 期
Does postoperative treatment with parathyroidea hormone Forteo®improve the disability inelderly patients undergoing spinal stabilization fusion surgery comparedwith patients treated with placebo. If that is the case, is there a correlationbetween improvement of disability and solid osseous healing?MedDRA version: 14.1Level: LLTClassification code 10041597Term: Spinal stenosis of lumbar regionSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersSpinal stenosisEUCTR2011-006152-36-DKMiddelfart Rygsektor100